Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Untersuchungen über die Wirksamkeit eines neuen fibrinolytischen Enzyms zur lokalen Thrombolyse am Scribner-Shunt

Zusammenfassung

Am Beispiel des Scribner-Shunts konnte gezeigt werden, daß es bei lokaler Applikation von Protease I (Astra), einem proteolytischen Enzym aus Aspergillus oryzae möglich ist, arterielle oder venöse Thromben in vivo aufzulösen. Relativ geringe Mengen von etwa 10–12 mg und kurze fermentative Einwirkungszeiten von 30–40 min führten dabei bereits zu eindeutigen Erfolgen, insbesondere auch bei arteriellen Thrombosen. Die Bestimmung der Inhibitorwerte vor und nach Anwendung der Protease ergab im Gegensatz zur generalisierten Zufuhr keine Veränderungen, so daß Nebenwirkungen einer allgemeinen thrombolytischen Therapie vermieden werden können. Als einzige Nebenwirkung wurden lokale Schmerzsensationen beobachtet, die nach einiger Zeit abklangen.

Summary

Coagulated Scribner shunts are very suitable for experimental studies on fibrinolysis. The proteolytic activity of Protease I, also described as Aspergillin 0 and CA 7, and derived from Aspergillus oryzae, has been studied in coagulated Scribner shunts. It has been shown that Protease I locally applied is able to dissolve arterial and venous thrombi in vivo. Compared with other fibrinolytic substances only small doses of Protease I (10–12 mg) and short periods of application (30–40 min) were necessary for shunt declottings. Determinations of the individual inhibitor levels before and after administration of Protease I showed, that the small doses of Protease I used locally in coagulated Scribner shunts did not cause change in the inhibitor levels. Therefore side effects of a systemic fibrinolytic therapy could be avoided. There were only local side effects consisting in transient pains along the cannulated vessels.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Clark, P. B., andF. M. Parsons: Routine use of the scribner shunt for haemodialysis. Brit. med. J.1966 I, 1200.

  2. 2.

    Clunie, G. J. A., A. M. Martin, andB. Nolan: Intermittent haemodialysis: Insertion and care of the silastic-teflon cannula. Brit. med. J.1967 I, 88.

  3. 3.

    Wing, A. J., J. R. Curtis, andH. E. de Wardener: Reduction of clotting in scribner shunts by long-term anticoagulation. Brit. med. J.1967 I, 143.

  4. 4.

    Fritzer, W., O. Jahn, W. Pinggera u.Oei Hong Jone: Kontrolluntersuchungen und Rekanalisation des Scribner-Shunts. Wien. Z. inn. Med.1, 161 (1967).

  5. 5.

    Anderson, D. C., A. M. Martin, G. J. A. Clunie, W. K. Stewart, andJ. S. Robson: Eight months' experience in the use of streptokinase locally for de-clotting arteriovenous cannulae. EDTA Proceedings4, 55 (1967)

  6. 6.

    Kjellstrand, C. M., B. Lindergård, andE. Boijsen: Treatment of clotted quinton-scribner arteriovenous shunts by streptokinase (Kabikinase®). Results evaluated by angiographic and resistance studies. EDTA Proceedings4, 61 (1967).

  7. 7.

    Gurland, H. J., H. H. Edel u.E. Renner: Die intermittierende Dauerdialysebehandlung chronisch Nierenkranker. Aus: Aktuelle Probleme der Nephrologie, S. 683. Berlin-Heidelberg-New York: Springer 1966.

  8. 8.

    Schmidt, H. W.: Thrombolyse durch Plasminogen-Aktivierung und durch direkte Proteolyse. Arzneimittel-Forsch.15, 132 (1965).

  9. 9.

    Schmidt, H. W.: Zur Thrombolyse mit verschiedenen Fibrinolytica. Klin. Wschr.44, 618 (1966).

  10. 10.

    Stefanini, M., andH. Marin: Fibrinolysis. I. Fibrinolytic activity of extracs from nonpathogenetic fungi. Proc. Soc. exp. Biol. (N.Y.)99, 504 (1958).

  11. 11.

    Bergkvist, R.: The proteolytic enzymes of Aspergillus oryzae. I. Methods for the estimation and isolation of the proteolytic enzymes. Acta chem. scand.17, 1521 (1963).

  12. 11a.

    II. Properties of the proteolytic enzymes. Acta chem. scand.17, 1541 (1963).

  13. 12.

    Bergkvist, R.: The proteolytic enzymes of Aspergillus oryzae. III. A comparison of the fibrinolytic and fibrinogenolytic effects of the enzymes. Acta chem. scand.17, 2230 (1963).

  14. 13.

    Bergkvist, R.: The proteolytic enzymes of Aspergillus oryzae. IV. On the inhibition of the enzymes by serum. Acta chem. scand.17, 2239 (1963).

  15. 14.

    Bergkvist, R., andP. O. Svärd: Studies on the thrombolytic activity of a protease from Aspergillus oryzae. Acta physiol. scand.60, 363 (1964).

  16. 15.

    Roschlau, W. H. E.: The evaluation in the dog of a proteolytic enzyme derived from Aspergillus oryzae. Canad. J. Physiol. and Pharmacol.42, 109 (1964).

  17. 16.

    Roschlau, W. H. E., andA. L. Tosoni: Thrombolytic therapy with CA-7 (Fibrinolytic enzyme from Aspergillus oryzae) in the dog. Canad. J. Physiol. and Pharmacol.43, 731 (1965).

  18. 17.

    Roschlau, W. H. E.: Systemic toxicity of CA-7 (Fibrinolytic enzyme from Aspergillus oryzae) in the dog. Angiology17, 882 (1966).

  19. 18.

    Hansson, E., andG. Magnusson: One month toxicity investigations in rats with Astra 1652 (Fibrinolytic agent) after intravenous administration. Persönliche Mitteilung 1967.

  20. 19.

    Hansson, E., G. Magnusson, S. Lindvall, andP. O. Svärd: One month toxicity investigations in dogs with Astra 1652 (Fibrinolytic agent) after intravenous administration. Persönliche Mitteilung 1967.

  21. 20.

    Hansson, E., andG. Magnusson: Three month toxicity investigations in rats with Astra 1652 (Fibrinolytic agent) after intravenous administration. Persönliche Mitteilung 1967.

  22. 21.

    Hansson, E., G. Magnusson, S. Lindvall, andP. O. Svärd: Three month toxicity investigations in dogs with Astra 1652 (Fibrinolytic Agent) after intravenous administration. Persönliche Mitteilung 1967.

  23. 22.

    Jürgens, J.: Effect in vivo on the spontaneous platelet aggregation of an enzyme from Aspergillus oryzae. Lecture on the First Int. Congr. of Platelets, Viviana Luckhaus Foundation, Buenos Aires 1965.

  24. 23.

    Jürgens, J.: Effect of an Aspergillus enzyme on platelet aggregation in humans. Life Sci.5, 1379 (1966).

  25. 24.

    Svärd, P. O.: The effect of an enzyme preparation from Aspergillus oryzae on the aggregation of rabbit platelets in vitro. Scand. J. Haemat.3, 277 (1966).

  26. 25.

    Bygdeman, S.: Effect of an Aspergillus enzyme on adenosine-diphosphate (ADP) induced platelet aggregation and adhesiveness. Life Sci.6, 499 (1967).

  27. 26.

    de Nicola, P., A. Gibelli, G. Turazza, andP. Giarola: Influence of an Aspergillus enzyme on ADP-induced Platelet aggregation and fibrinolysis. Life Sci.6, 1233 (1967).

  28. 27.

    Jürgens, J.: Thrombolytische Therapie, S. 56, 57, 154. Stuttgart: Schattauer 1966.

  29. 28.

    O'Brien, E. T., R. D. Thornes, D. O'Brien, andB. Hogan: Inhibition of antiplasmin, and fibrinolytic effect of protease in patients with cancer. Lancet1968 I, 173.

  30. 29.

    Roschlau, W. H. E., andA. M. Fisher: Thrombolytic therapy with local perfusions of CA-7 (Fibrinolytic enzyme from Aspergillus oryzae) in the dog. Angiology17, 670 (1966).

  31. 30.

    Tsapogas, M. J., andP. T. Flute: Experimental thrombolysis with streptokinase and urokinase. Brit. med. Bull.20, 223 (1964).

  32. 31.

    Lindvall, S.: Determination of inhibitors in plasma and serum. Part I. and II. To be published 1968.

  33. 32.

    Bennhold, I., P. Froese, A. Scholz, andM. Kessel: Shunt declotting with a new locally applied thrombolytic agent. EDTA Proceedings5 (1968) (in press).

  34. 33.

    Nilsson, I. M.: Trombosmekanismen. Nord. Med.78, No 39 (1967).

  35. 34.

    Åström, A.: Persönliche Mitteilung 1967.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kessel, M., Bennhold, I. & Froese, P. Untersuchungen über die Wirksamkeit eines neuen fibrinolytischen Enzyms zur lokalen Thrombolyse am Scribner-Shunt. Klin Wochenschr 46, 1263–1266 (1968). https://doi.org/10.1007/BF01711871

Download citation